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Abstract Immunisation of the newborn represents a key
global strategy in overcoming morbidity and mortality due
to infection in early life. Potential limitations, however, in-
clude poor immunogenicity, safety concerns and the develop-
ment of tolerogenicity or hypo-responsiveness to either the
same antigen and/or concomitant antigens administered at
birth or in the subsequent months. Furthermore, the neonatal
immunological milieu is polarised towards Th2-type immuni-
ty with dampening of Th1-type responses and impaired hu-
moral immunity, resulting in qualitatively and quantitatively
poorer antibody responses compared to older infants. Innate
immunity also shows functional deficiency in antigen-
presenting cells: the expression and signalling of Toll-like
receptors undergo maturational changes associated with dis-
tinct functional responses. Nevertheless, the effectiveness of
BCG, hepatitis B and oral polio vaccines, the only
immunisations currently in use in the neonatal period, is proof
of concept that vaccines can be successfully administered to
the newborn via different routes of delivery to induce a range
of protective mechanisms for three different diseases. In this
review paper, we discuss the rationale for and challenges to
neonatal immunisation, summarising progress made in the
field, including lessons learnt from newborn vaccines in the
pipeline. Furthermore, we explore important maternal, infant
and environmental co-factors that may impede the success of
current and future neonatal immunisation strategies. A variety
of approaches have been proposed to overcome the inherent
regulatory constraints of the newborn innate and adaptive im-
mune system, including alternative routes of delivery, novel
vaccine configurations, improved innate receptor agonists and
optimised antigen-adjuvant combinations. Crucially, a dual
strategy may be employed whereby immunisation at birth is
used to prime the immune system in order to improve immu-
nogenicity to subsequent homologous or heterologous
boosters in later infancy. Similarly, potent non-specific immu-
nomodulatory effects may be elicited when challenged with
unrelated antigens, with the potential to reduce the overall risk
of infection and allergic disease in early life.
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Introduction
TheWorld Health Organisation (WHO) estimates that 45% of
deaths among children under the age of 5 years occur during
the newborn period [1]. More specifically, neonatal infections
currently account for ~ 700,000 of these deaths and ~ 7million
cases per year, with the greatest proportion affected and most
severe outcomes in poorly resourced areas [2]. The burden of
disease is high at this early stage due to the unique nature of
the neonatal immune system specifically adapted to postnatal
life, but simultaneously susceptible to infection and subopti-
mal vaccine responses. The transition from the sheltered in-
utero environment to the ‘outside world’, the lack of defence
from vaccine-induced antibody and the profile of early path-
ogenic organisms all contribute to the newborn’s vulnerability
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to microbial and environmental insults. Despite the limited
ability of the neonatal immune system to develop potent mem-
ory responses, the success of the three vaccines administered
in the immediate neonatal period, Bacillus Calmette–Guérin
(BCG), hepatitis B vaccine (HBV) and oral polio vaccine
(OPV), confirms that newborn vaccination can be effective
at preventing three quite different diseases [3]. Furthermore,
recent technological advances have enabled in vitro and
in vivo modelling of early immune ontogeny with detailed
characterisation of mechanistic processes. Along with the in-
troduction of several significant global policy and funding
initiatives to promote newborn and infant health, this has re-
sulted in renewed interest in neonatal immunisation as an im-
portant tool to reduce the unacceptably high figure of neonatal
mortality [4].
The rationale for newborn vaccination
Neonatal immunisation would provide early protection for
newborns and infants, narrowing the critical period of vulner-
ability intrinsic to routine vaccination schedules that start later
in life. Other immunological advantages have also been
hypothesised: fewer vaccine doses may be required if an im-
munogenic response is elicited at this early stage; there may be
a general immunomodulatory effect, boosting immunity from
birth before exposure to viral or bacterial pathogens [3, 5, 6].
Equally, neonatal vaccination is easily implementable, given
that birth is a crucial point of contact with healthcare systems
globally; as such, effective newborn vaccines would achieve
high population penetration, particularly important in poorly
resourced areas with otherwise limited health care services [6].
The ideal neonatal vaccine
Important concepts for the successful development and impact
of a neonatal vaccine include safety, immunogenicity and ef-
ficacy in addition to the establishment of a balance between
reactogenicity/autoimmunity and immune tolerance [7, 8].
Ideally, a vaccine would be administered at birth (or before
4 weeks of age), via the oral rather than the intramuscular or
subcutaneous routes, safely eliciting a strongly protective re-
sponse after a single dose with minimal interference from
maternal antibodies [3]. This response would be sustained or
easily boosted as part of the subsequent routine infant
immunisation schedule, without developing hypo-
responsiveness when challenged with the same or concomi-
tant vaccine antigens.
In this review article, we will discuss key features of the
three vaccines currently recommended for use at birth.
Furthermore, we will assess the main maternal, infant and
environmental factors that may affect and/or hinder the suc-
cess of future neonatal vaccines. Finally, we will summarise
new strategies in the pipeline and remaining challenges to be
addressed in the future.
Systemic challenges to the use of vaccines
in the neonatal period
Immunogenicity
The main challenge to successful immunisation of newborns
is achieving sufficient immunogenicity in the context of de-
veloping innate and adaptive immunity, primarily due to the
distinct nature of neonatal leukocytes [2, 9, 10]. Crucially, the
neonatal immunological milieu is skewed towards Th2-type
immune responses, with dampening of Th1-type immunity
and inflammasome pathways [4, 11–13]. These adaptations
prevent alloimmune reactions between the mother and fetus,
enable microbial colonisation and avoid excess proinflamma-
tory responses [6, 10, 14]. Conversely, they render the new-
born susceptible to infection and limit optimal vaccine re-
sponses [15, 16].
Neonatal CD4+ T cells are primarily recent thymic emi-
grants shown to have reduced immune function [17, 18].
Preferential CD4 T cell differentiation into Th2 effectors is
thought to be partly mediated by epigenetic processes, specif-
ically hypermethylation of IFNγ locus and hypomethylation
of the Th2 locus [19]. This is further enhanced by the reduced
capacity of antigen-presenting cells (APCs) to produce Th2-
polarising cytokines, notably IL12 [2, 20]. Th1 cells also ex-
press IL4Rα/IL13Rα heteromeric receptors, with high risk of
subsequent apoptosis on ligation with IL4, a product of Th2
cells [21]. Moreover, there is a qualitative and quantitative
increase in suppressive T regulatory cells which secrete high
concentrations of IL10 and TGFβ, promoting tolerogenicity
of APCs and limiting effector T cell responses [5, 22, 23].
In addition to these classic Th1/Th2 responses, Th17 pro-
inflammatory responses might also contribute to an important
component of vaccine-induced memory [2]. Production of
Th17 cell promoting cytokines IL6 and IL23 dominates in
term infants [24].
Humoral immunity in neonates is impaired with a subse-
quent need for repeated vaccine doses; lower antibody titres
are secreted with a narrower antibody repertoire and subopti-
mal functional responses to some antigens when compared to
older infants [3, 10, 25]. This reflects defects in neonatal B cell
differentiation, with dominance of memory B cells versus
plasma cells (PC), resulting in limited extrafollicular (EF)
and germinal cell (GC)-derived plasma cell responses. This
can be explained by both B cell-intrinsic and B cell-extrinsic
factors: the former includes weaker B cell receptor-mediated
signalling in naïve B cells, the lower expression of co-
stimulatory molecules for T cells and the slow maturation of
marginal zone B cells that recognise pathogen-associated
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molecular patterns (PAMPs) with subsequently reduced T-
independent responses [25]. A key B cell extrinsic factor is
the limited help provided by follicular dendritic cells (FDC)
and/or T follicular helper (TFH) cells (the latter is mediated by
IL12 which is reduced), thereby delaying GC induction
[26–28]; dendritic cell activation signals and survival factors,
such as A Proliferation Inducing Ligand (APRIL), are also
suppressed [2, 27, 29]. On the other hand, high concentrations
of adenosine in neonatal plasma selectively inhibit production
of Th1-polarising cytokines via intracellular mechanisms, in-
cluding induction of cyclic adenosine monophosphate
(cAMP) [30, 31].
Given the limited exposure to antigens in utero, neonates
are particularly dependent on their innate immunity to prime
adaptive immune responses [32]. The unique characteristics of
the newborn’s innate immunity are therefore critical in
explaining why they have suboptimal vaccine responses in
comparison to older infants [5, 33]. Above all, the functional
activity of neonatal APCs is impaired, primarily because they
express pattern recognition receptors (PRR), such as Toll-like
receptors (TLRs), with distinct functional responses including
limited antiviral and Th1-polarising cytokine production to
most stimuli [2, 34, 35]. This cytokine ontogeny is thought
to be due to epigenetic changes as well as differences in ac-
tivity of interferon response factor (IRF) transcription factors.
For example, there is impaired nuclear translocation of IRF7
thereby inhibiting transcription of IFNα and IFNβ; reduced
IRF3 DNA binding activity and association with the co-
activator CRB-binding protein (CBP) also lead to lower type
1 IFN production [24]. However, the precise molecular mech-
anisms underlying TLR-mediated innate function in early life
have not been fully delineated and require further attention,
since their potentiation would help to induce Th1 and TFH
cell responses, thereby overcoming newborn adaptive im-
mune deficiencies [5].
All vaccines are not equal
The impact of immunisation on this unique neonatal im-
mune regulation milieu may vary between vaccine types.
Infants immunised at birth with HBVor OPV develop low-
er Th1 type responses than adults. However, such Th1 re-
sponses are associated with higher antibody responses than
in adults receiving booster doses [36, 37]. By contrast, it is
now well established that BCG induces potent mature Th1
responses in newborns [38].
Multiple studies have explored the variable capacity of
different vaccines to induce appropriate Th1 responses at
birth, identifying determining factors such as antigen dose,
type of adjuvant and route of administration [11, 13, 15].
Above all, the ability of APCs to potentiate adaptive immune
responses plays a crucial role [5].
Immune interference and hypo-responsiveness
There is theoretical concern that neonatal vaccination may
result in the subsequent development of immune hypo-re-
sponsiveness, particularly when challenged with either the
same antigen (‘immune paralysis/tolerance’) and/or con-
comitant antigens (‘vaccine interference’) in subsequent in-
fant immunisation schedules [3, 6, 39].
Halasa et al. demonstrated that the administration of an
additional dose of diphtheria, tetanus, acellular pertussis
(DTaP) at birth was safe but also associated with significantly
reduced antibody response to three of the four pertussis anti-
gens (pertussis toxin and pertactin at 6, 7 and 18 months and
fimbrae at 6, 7, 17 and 18 months) and to diphtheria antigens
at 7 months when compared with controls. Immune responses
to all other vaccine antigens were comparable including HBV
and tetanus toxoid [40].
By contrast, Knuf et al. showed that priming at birth with
a three-component standalone aP vaccine was well tolerated
and resulted in significantly higher antibody responses to
the three pertussis antigens at 3 months of age (after the first
dose of DTaP vaccine had been given) in comparison to
controls. Early neonatal immunisation with aP did not elicit
immunologic tolerance to pertussis antigens, with all sub-
jects reaching antibody concentrations above the protective
threshold 1 month after completing the vaccine course, al-
though it did dampen responses toHaemophilus influenza B
(Hib) and HBV vaccines [41]. Given that the maternal anti-
body levels in newborns were comparable in both studies,
their contrasting results were thought to be secondary to the
different vaccine formulations and/or adjuvants used or to
the additional birth dose of HBV given in the former trial.
Furthermore, Knuf et al. have proposed that the robust sec-
ondary T cell pertussis-specific responses, induced after the
first DtaP-IPV-HBV/Hib vaccine dose, may have subse-
quently interfered with adequate recruitment of CD4+ T
cells needed to activate a strong primary response to con-
comitantly administered HiB and HBV antigens, known as
‘bystander interference’ [41, 42].
Other studies using different vaccines have disputed this
concept of immune downregulation. As part of the large
randomised, multi-centre clinical trial of BCG given at
birth, the Danish Calmette Study, Nissen et al. investigated
the effect of BCG at birth on the antibody response to the
three routine vaccines against DTaP-IPV-Hib and Prevenar
13 in a subgroup of participants. BCG did not reduce the
probability of having antibody titres above the limit of pro-
tection with seroprotective levels detected for each of the
three vaccinations in almost all children 4 weeks post vac-
cination. There was also no difference between BCG and
controls with respect to geometric mean concentrations
(GMC) of antibody even when adjusted for the background
factors [43]. Similarly, no interference has been observed
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between OPVand the vaccines administered alongside it as
part of the WHO routine immunisation schedule [44].
What can we learn from vaccines currently
administered to neonates?
Bacillus Calmette–Guérin
BCG is a live attenuatedMycobacterium bovis vaccine admin-
istered within the first few days of life in most countries to
prevent tuberculous (TB) meningitis and disseminated TB
disease in children. It is the most widely used vaccine world-
wide with an overall excellent safety record. Adverse reac-
tions range from localised inflammation and scarring at the
site of inoculation (95% of healthy neonates) to more serious,
systemic events including axillary and cervical lymphadenop-
athy and, very rarely (< 1 in million), disseminated BCG in-
fection [45, 46].
As yet, no surrogate immune marker of BCG-induced
protection has been identified [47]. Clinical markers of its
efficacy are used instead. Crucially, there is 73% protective
efficacy against TB meningitis and 77% against miliary TB
[45]. However, there is no convincing protection against
primary pulmonary infection or reactivation of latent TB,
and protective efficacy declines to non-significant levels
after 10–20 years [45, 48, 49]. Moreover, BCG efficacy is
variable and may depend on several factors including the
immune status of the recipient [50], prior exposure to envi-
ronmental mycobacteria (both M. tuberculosis and non-
tuberculous mycobacteria) [51], strain variation in BCG
preparations [52] although this has been contested [53],
genetic or nutritional variability and environmental factors
including sunlight exposure and poor cold-chain mainte-
nance [6, 51]. Prior exposure is thought to both limit repli-
cation of BCG and/or confer protection equivalent to BCG
(‘masking’). Given that this is dependent on age, it would
explain why mycobacteria-naïve newborns appear to bene-
fit more from BCG vaccination than older individuals [53].
BCG does not contain any exogenous adjuvant but is in-
herently ‘self-adjuvanted’ because Mycobacteria induce im-
mune responses via TLR2, TLR4 and TLR8 [52]. BCG in-
duces a potent Th1 polarised immune response to mycobac-
terial antigens, thereby overcoming the common obstacle
faced by newborn vaccinations and confirming that reduced
Th1 capacity in neonates is not absolute [54]. Studies among
infants demonstrate BCG-associated induction of CD4+ and
(to a lesser extent) CD8+ T cells, IFNγ, IL2, TNFα and
polyfunctional CD4+ T cells [55]. However none of these
responses were found to correlate with protection against TB
in BCG-immunised infants [56].
Neonatal BCG vaccination may also have non-specific, het-
erologous beneficial effects, boosting the innate and adaptive
immune responses to unrelated antigens and reducing morbid-
ity and mortality from non-tuberculous infections as well as
allergic diseases [57–62]. The nature and significance of such
effects, however, remains controversial and it cannot be ex-
cluded that neonatal vaccination may have a similar masking
effect on vaccines administered later in infancy, as already
observed between early exposure to (environmental)
mycobacteria and BCG [63–66].
Ota et al. demonstrated that BCG boosted cytokine and
antibody responses to unrelated vaccine antigens (HBV and
OPV) in neonates, probably by influencing maturation of den-
dritic cells. The finding that both Th1 and Th2 cytokines in-
creased suggests that the magnitude but not the quality of
neonatal responses to vaccines was influenced by BCG [38].
Similarly, an Australian study found that BCG was associated
with significantly higher response of several subclasses of the
pneumococcus conjugate vaccine (PCV) routinely given dur-
ing childhood [67].
Although the underlying immunological mechanisms have
not been fully elucidated, two hypotheses have been proposed
for these non-specific effects: ‘trained innate immunity’ and
‘heterologous immunity’. ‘Trained innate immunity’ de-
scribes the ability of the innate system to generate immuno-
logical memory and therefore be ‘trained’ to provide partial
protection against subsequent infections, independent of clas-
sical T and B cell adaptive immunity [68–70]. Natural killer
(NK) cells and monocytes have emerged as central to trained
immunity in mammals via functional reprogramming of PRR
(e.g. NOD2 receptor) [71, 72]. Primary exposure to microbial
ligands alters the fate of monocytes, dependent on the nature
and concentration of the ligand, mediated by epigenetic mech-
anisms at the level of H3K4 trimethylation [71].
The second immunomodulatory process proposed is ‘het-
erologous immunity’. This describes the effects on the adap-
tive immune system, primarily Tcell-mediated cross reactiv-
ity between vaccine-related and vaccine-unrelated antigens.
As such, Tcell vaccine responsesmay be impacted andmod-
ified by encounters with pathogens from previous infections
[71, 73, 74]. Although theWHO recently recommended that
the existing evidencewas insufficient to prompt a revision of
immunisation policy, further studies are required to charac-
terise the magnitude, duration and mechanisms of the non-
specific effects of vaccines and, therefore, their potential im-
plications for infant health [65, 66].
Hepatitis B vaccine
There is extensive evidence of the excellent safety and immu-
nogenicity profile of hepatitis B vaccines. Administration of
HBV, in some cases with hepatitis B immunoglobulin (HBIG),
remains the most effective way of preventing the high risk of
mother-to-infant transmission of HBV [6, 75–77], and it has
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been demonstrated that timely administration of the birth dose
results in the highest vaccine effectiveness.
The current widely used r-HBsAg vaccines, available
since 1986, are a viral subunit that has been transfected with
a plasmid that contains the S gene (codes for HBsAg) either
as a single preparation or in combined form. Alum, a chem-
ical compound containing aluminium salts, is added as
adjuvant.
The vaccine is highly immunogenic and induces potent
neutralising antibody following a series of at least three
doses. Recommended vaccination schedules that include a
birth dose will prevent most perinatally acquired infections
and offer early protection from horizontal transmission.
Anti-HBs antibodies are a marker of immunity and a titre
of anti-HBs antibodies to HBVsAg ≥ 10 IU/L indicates
seroprotection if measured 1–3 months after completion of
the primary immunisation series. In healthy infants, 30–40%
protection against HBV infection is achieved with one dose of
the vaccine, 50–75% protection with two doses and > 90%
with three doses [6].
Four intramuscular vaccine doses are recommended in
susceptible infants over the first year of life in the UK (three
in the USA). Side effects are generally mild including pain
at the injection site (3–29%), mild fever > 37.7 °C (1–6%),
malaise, headache, arthralgia and myalgia [6]. HBV
immunisation induces at least equivalent antibody re-
sponses in newborns and adults; this suggests that the ca-
pacity of the newborn to develop antibody responses de-
pends on the nature of the immune stimulus [9, 36].
Moreover, the success of the HBV schedule confirms that
vaccination at birth can elicit potent memory B cell re-
sponses that promote immunogenicity of subsequent vac-
cine booster doses, irrespective of primary antibody re-
sponse [5, 44].
Long-term protection against HBV infection depends on
the persistence of strong immunological memory and can
vary between individuals. After primary immunisation with
HBV vaccine, anti-HBs concentrations wane quite rapidly
within the first year and more slowly thereafter. However,
even if anti-HBs concentrations decline to below 10 IU/L,
immune memory continues to persist over a longer time
period. Booster doses are not currently recommended for
fully vaccinated, immunocompetent individuals.
Similar to the immune response to HBV infection, T cell
dependence of the immune response to hepatitis B vaccination
has been demonstrated, and it was shown that non-responding
infants had a reduced capacity to adequately expand and dif-
ferentiate TH cells.
The T cell responses elicited by HBV have been shown
to vary between newborns and adults. A study by Ota et al.
demonstrated lower interferon-γ production (reflective of
Th1 immunity) but higher Th2 memory responses in those
vaccinated at birth when compared with adults [36].
Oral polio vaccine
Two types of polio vaccines are in use worldwide: intramus-
cular (or subcutaneous) inactivated polio vaccine (IPV) and
orally administered, live attenuated polio vaccine (OPV). In
polio-endemic countries and in areas at high risk for importa-
tion and subsequent spread, WHO also recommends an OPV
dose at birth (called ‘zero’ dose), followed by the primary
series of three OPV doses with at least one IPV dose [78].
OPV therefore remains the first mucosal vaccine received by
most newborns in low- to middle-income countries. A triva-
lent OPV formulation (tOPV) was used worldwide until April
2016 when it was replaced with bivalent type 1 and type 3
OPV (bOPV) during a global synchronised switch.
Withdrawal of type 2 OPV was required because type 2 wild
polioviruses no longer circulate, and its continued use had
been responsible for a disproportionate number of vaccine-
associated paralytic polio (VAPP) and circulating vaccine-
derived polioviruses (cVDVP) cases [78]. There is no extrin-
sic adjuvant within the OPV formulation; instead, it contains
single-stranded RNAwhich activates the innate immune sys-
tem by stimulating TLR8 [79].
Halsey et al. comprehensively summarised a large dataset
obtained from different countries, using serological assays
where results were adjusted for estimated decline of maternal
antibody, and viral excretion assays in stool [44]. Overall, the
summary data demonstrate that when administering a dose of
tOPVand DTP in the first week of life, 50–100% of newborns
will benefit by developing active intestinal infections and lo-
cal immune responses, while 30–70% of neonates develop
serum antibodies to one or more poliovirus types. The wide
confidence intervals are explained by a number of factors such
as persisting maternal antibody at time of vaccination,
breastfeeding, varying intervals of administration after birth
and a range of geographic settings. Based on these data, the
authors recommended the use of tOPV at birth in high risk
areas where poliomyelitis has not been controlled [44].
A subsequent Egyptian trial confirmed the immunogenicity
of a monovalent type 1 OPV given at birth and its superiority
over previous trivalent formulations. Fifty-five percent of
newborns in the monovalent-vaccine group seroconverted
30 days after priming. Nearly half of infants with high mater-
nal antibody titres still secreted antibodies against type 1 po-
liovirus. Following challenge with type 1 OPVat 1 month of
age, 75% of infants did not excrete type 1 IPV [80].
By contrast, a study in Belgium used OPV as a model of
early immunisation to investigate the capacity of young in-
fants to develop cellular immune responses. They showed that
weak IFNγ and cell-mediated responses (i.e. limited Th1 re-
sponses) to polio antigens were induced post neonatal OPV
when compared to immune adults. However, the titre of
neutralising antibodies was high, above the protective thresh-
old, similar to previous studies [37].
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In summary, the considerable experiences with existing
vaccines have shown that newborns are in fact able to mount
robust immune responses to neonatal vaccines, particularly to
live attenuated vaccines, but that such responses are influ-
enced by a number of co-factors, as discussed in later sections.
What can we learn from vaccines that have been
investigated for use in neonates but are not currently
part of recommended regimens?
Pneumococcal vaccines (PCV)
Two recent trials have demonstrated that the delivery of seven
valent pneumococcal conjugate vaccine (PCV7) to neonates
may be safe and immunogenic, with no evidence of hamper-
ing potential long-term protection or inducing immune toler-
ance. The first trial, undertaken in Kenya, randomised young
infants to either receive seven-valent PCV at 6, 10 and
14 weeks (EPI group) or 0, 10 and 14 weeks (neonatal group).
Serotype-specific serum IgG and avidity were measured at
birth and 6, 10, 14, 18, 36 and 37 weeks. Infants were then
boosted with either seven-valent PCV or one fifth dose of
pneumococcal polysaccharide vaccine at 36 weeks. Results
demonstrated excellent safety with minimal adverse effects.
At both 18 and 36 weeks, there was no significant difference
in the proportion of IgG above the protective threshold against
each serotype between infant groups. However, geometric
mean concentrations (GMCs) were lower in the neonatal
group for serotypes 4, 9V, 18C and 19F at 18 weeks and for
serotype 4 at 36 weeks. By contrast, avidity was significantly
higher in the neonatal compared to the control group for sero-
types 4, 6B and 19F at 18 weeks and for serotype 19F at
36 weeks likely because affinity maturation would have oc-
curred for longer since birth. The clinical significance of these
avidity findings is uncertain and it could be argued that lower
GMC could lead to non-protective responses at an earlier
stage. However, this did not occur during the follow-up period
of 37 weeks. Response to the 36-week boosters and preva-
lence of vaccine-type/non vaccine-type carriage were compa-
rable between groups, suggesting absence of immunological
tolerance after neonatal vaccination [81, 82].
Similarly, Pomat et al. conducted an open randomised trial
in Papua New Guinea to compare infants given PCV7 in a 0-
1-2-month (neonatal) schedule with that of the routine 1-2-3-
month (infant) schedule. All infants received 23-valent pneu-
mococcal polysaccharide vaccine (PPV) at age 9 months. By
2 months of age, GMCs for serotypes 4, 9V, 18C and 19F
were significantly higher in the neonatal than in the infant
group, taking into account that the neonatal group had re-
ceived two doses of PCV7 compared with the single dose in
the infant schedule. Post-hoc analysis of the differences in
proportions of children with protective antibody levels at age
2 months did not demonstrate superiority of two doses in the
neonatal group over one dose in the infant group. While all
antibody responses to vaccine types in the neonatal group
were non-inferior to those in the infant group at age 2 months,
over time the infant-immunised group generally had higher
Ab levels than the neonatal-immunised group. On subsequent
challenge with PPVat 9 months, significantly higher serotype-
specific IgG concentrations above the protective threshold
were induced in PCV7 primed compared to unprimed infants;
neonatal and infant groups had equivalent antibody levels,
which persisted until the end of follow-up at age 18 months.
These results again suggest an absence of tolerance following
neonatal PCV vaccination [82, 83].
Pertussis vaccines
Immunisation within 24 h of life with whole cell pertussis or
combined with diphtheria and tetanus vaccines has previously
demonstrated a good safety profile, with nomoderate or major
adverse effects documented [84]. Th1-type immunity was
preferentially induced, in a similar way to BCG. However,
the serological response was suboptimal and a reduced re-
sponse to pertussis boosters was documented in 75% of study
subjects until 5 months of age, independent of maternal anti-
body titre which was low. This can probably be attributed to
antigen-specific immunological hypo-responsiveness, already
discussed previously. By contrast, if immunisation was de-
layed to 3 weeks of age, the serological response was adequate
[85, 86]. Based on these findings, the WHO recommends
starting pertussis immunisation schedules from 6 weeks of
age.
Due to the recent resurgence of severe pertussis in early
life, there has been renewed interest in administering aP vac-
cines at birth, either as a sole vaccine or as part of DTaP
combined vaccine. The results of these studies have been con-
flicting, as discussed previously, with concerns regarding
tolerogenicity both to the same antigen administered later in
infancy or ‘bystander interference’ to concomitant antigens.
[40, 41, 87, 88]
Vaccines against viral pathogens
The high burden of respiratory and gastrointestinal disease in
early life warrants the further study and development of neo-
natal vaccines against RSV, parainfluenza, influenza and rota-
viruses, ideally administered via the oral or nasal route to
induce effective mucosal immunity. Neonatal immunisation
against RSV is currently under consideration with several vac-
cine candidates under development, but none has yet
progressed to licencing [89].
A recent pilot study enrolling 66 infants into two equally
sized groups comparing pentavalent rotavirus vaccine (RV5)
administered on an early alternative dosing schedule (at 2–
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5 weeks of age) compared with RV5 administered on the
current WHO standard schedule, measuring safety, serum-
neutralising antibody (SNA) and IgA geometric mean titers
(GMTs). RV5 was found to be generally well tolerated and
immunogenic in the neonatal period, although the rotavirus
SNA serotype 4 response was less robust in newborns than in
infants on the standard schedule [90].
Co-factors affecting responses to newborn vaccines
Maternal infections and maternal antibody
The maternal factors potentially affecting the success of neo-
natal immunisation are threefold: maternal-fetal transfer of
antibodies, maternal-fetal transfer of pathogenic organisms
and chronic maternal infections.
Maternal antibodies, transplacental or milk-derived, may
potentially interfere with the neonatal adaptive immune re-
sponse and subsequent vaccine responses [91, 92]. This has
already been shown in the context of maternally derived anti-
bodies inhibiting immunogenicity of the measles vaccine in
infants [93]. The suppressive effect is thought to depend on
the ratio between antibody titre and vaccine antigen dose,
given that circulating antibodies hide the antigen from the
host’s immune cells thereby masking B cell epitopes [92].
This is exacerbated by the unique nature of the neonatal Fc
receptor which increases the serum half-life of passively trans-
ferred antibodies [5, 94]. By contrast, other studies have
shown that the infant’s APC uptake and T cell responses ap-
pear to be largely unaffected by maternal antibody [13].
Further research is currently ongoing to gain better mechanis-
tic insights. Antibodies in breast milk may similarly limit the
efficacy of oral vaccines at the mucosal surface, although this
has been contested [95–97]. A recent study by Ali et al. dem-
onstrated that withholding breastfeeding around the time of
rotavirus vaccine administration did not improve vaccine im-
munogenicity with no increase in anti-rotavirus IgA serocon-
version measured [98].
Transmission of pathogens across the placenta to the infant
can also play a role in early life immunity with a potential
impact on newborn vaccine responses: HIV-associated im-
mune compromise, particularly cellular immune deficiency,
exacerbates poor neonatal vaccine outcomes and some ad-
verse effects. In a study carried out in South Africa between
2004 and 2006, the pooled incidence of disseminated BCG
was estimated to be as high as 992 per 100,000 HIV-infected
vaccinees, almost 1000 times higher than those who were
HIV-uninfected [99]. The mortality rate associated with dis-
seminated BCG disease was > 70% [99, 100]. Other patho-
gens that are vertically transmitted and may potentially affect
neonatal immunity include toxoplasmosis, rubella, CMVand
other herpes viruses, syphilis, enterovirus, parvovirus B19 and
hepatitis viruses. A comprehensive discussion of the impact of
each disease on vaccine responses is beyond the scope of this
review.
Chronic maternal infections may shape neonatal vaccine
responses by their impact on maternal antibody transfer across
the placenta or their generalised effect on the developing neo-
natal immune system. This occurs independently of vertical
transfer of pathogenic organisms and is secondary to exposure
to microbial antigens, either free or complexed with immuno-
globulins crossing the placenta. Subsequently, there is sensi-
tisation in-utero and induction of adaptive, inflammatory and
regulatory responses [101]. The unique maternal disease pro-
file during pregnancy may contribute to the observed differ-
ences in immune responses of infants in developed compared
to developing countries [102].
During pregnancy, prevalence of infection with at least one
helminth species is 10–70% in endemic regions [101].
Detection of specific immunoglobulins, particularly IgE, to
various helminth species in cord blood reflects in-utero sensi-
tisation of both B and T lymphocytes to microbial antigens,
while parasites are rarely transmitted vertically [103, 104].
Poor T cell responses to tetanus toxoid (TT) immunisation
and reduced HiB vaccine-specific antibody responses have
been reported in neonates born to mothers with lymphatic
filariasis and/or schistosomiasis [105]. Furthermore,
Malhotra et al. found that Kenyan infants born to mothers
infected with Schistosoma haematobium and sensitised in
utero had lower IFNγ responses to BCG than did unexposed
infants [106]. A similar pattern was seen in the context of
maternal filariasis during pregnancy [106]. By contrast,
Elliot et al. concluded that maternal helminth infection may
have little, if any, adverse effects on the outcome of infant
immunisation. Of note, only maternal Mansonella perstans
infection was associated with significantly higher IL10 re-
sponses to BCG and tetanus immunisation but with no reduc-
tion in IFNγ, IL5 and IL13 responses [107].
Maternal infection with Trypanosoma cruzi and congenital
Chagas disease induces a trend to type 1 polarisation of infant
immune responses to vaccines. High levels of IFNγ were
noted in response to BCG administered in exposed but unin-
fected infants compared with congenitally infected infants or
unexposed and uninfected infants [108].
Data on vaccine responses of HIV exposed but uninfected
newborns are conflicting. On one hand, studies have found
that their humoral and cell-mediated responses to vaccines,
including to the measles vaccine and BCG, are similar to
responses in unexposed infants [109, 110]. Moreover, Jones
et al. demonstrated that HIV exposed uninfected infants born
in South Africa mounted higher increments of antibody re-
sponses to pertussis and pneumococcus vaccines [111]. This
may be because the reduced transfer of specific maternal an-
tibodies noted in this cohort mitigated the poor vaccine-
induced humoral responses seen in early infancy [33]. The
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same research group also studied the impact of maternal HIV
infection and demonstrated that HIV exposed, uninfected in-
fants have normal responses to BCG vaccination administered
at birth. T cell subsets are affected, however, which likely
reflects priming of the developing immune system even in
the absence of infection. Similarly, sensitisation to
mycobacteria resulted in a positive correlation between mater-
nal and newborn levels of BCG-specific CD4 T cells. This
again suggests that maternal cellular responses may shape
the infant response to BCG antigen. Following administration
of BCG at 6 weeks of age, however, no difference in subse-
quent BCG-specific T cell proliferative responses or cytokine
induction was documented at 16 weeks of age between those
infants with either exposure to maternal HIVand/or latent TB
[112]. Therefore, any effects of maternal HIVand possible TB
infection on infant immune profiles at birth are considered
transient, as long as the infant remains uninfected. Given this,
HIVexposed, uninfected infants are equally likely to respond
to and be protected by BCG vaccination as HIV unexposed
infants [33, 112]. Not all studies, however, currently agree on
this conclusion. Data from two Brazilian studies suggests that
HIV exposed but uninfected infants have altered T cell re-
sponses to BCG with lower TT- and HBV-specific antibody
levels [113, 114].
Finally, placental malaria, secondary to maternal infection
with Plasmodium falciparum or Plasmodium vivax, may im-
pact neonatal immunity and vaccine responses. Above all,
placental malaria is associated with reduced transfer of specif-
ic maternal antibodies, including RSV, varicella zoster, herpes
simplex and measles and TT [115–117]. This may be due to
pathological changes in the placental structure in endemic
settings, with subsequent damage to Fc receptors [89,
115–117]. Furthermore, similar antibody and T lymphocyte
responses to TTwere noted in infants born to mothers with or
without placental malaria [118]. Ultimately, further work is
required to elucidate these effects. The mechanisms may be
similar to those proposed in maternal HIV, in that the limited
transfer of maternal antibody may overcome potential
blunting of neonatal humoral responses to early vaccination.
Neonatal co-factors
In addition to maternal factors, genetic variation among hosts
plays a key role in the observed heterogeneity of neonatal and
infant vaccine responses [119]. Marchant et al. measured anti-
body responses to tetanus toxoid, measles and total IgG in 210
Gambian twin pairs, estimating the environmental versus genetic
components of any variation documented. They found that ge-
netic determinants control the early phase of the vaccine antibody
response, while the environment predominantly influences anti-
body persistence and avidity maturation [120]. More recently,
further studies have applied genome-wide association studies in
order to attempt to identify the genetic determinants of different
vaccine responses against hepatitis B, measles and rubella [121].
The quantity and quality of innate and adaptive responses to
newborn immunisation are further impaired in babies born pre-
maturely. As such, the concerns regarding immunogenicity and
safety are even more marked, particularly given the lack of
detailed immunological studies in this age group, mainly limited
by the small amounts of blood available [122, 123]. For a num-
ber of antigens, the humoral response to initial vaccine doses
may be lower than that of term infants, but the protective thresh-
old is often reached and memory successfully induced, some-
times with an additional dose to achieve persistence of protec-
tion [123]. Again, the lower titres of maternal antibodies seen in
prematurity may enhance this effect. On the other hand, it is
widely accepted that HBV is less immunogenic in preterm in-
fants with birth weights < 2 kg than in term infants [124, 125].
Nevertheless, unless they have underlying medical complica-
tions, these infants respond to HBV by 30 days of age regardless
of birth weight or gestational age [124].
Baxter et al. concluded that immunogenicity in this cohort
is vaccine specific: robust responses are seen following TT
and inactive preparations; however, subunit formulations are
less optimal. As such, they recommend administering addi-
tional booster doses and/or serology testing for infants
< 32 weeks [122]. Further research in this area would give
important insights into the ontogeny of the maturing fetal and
neonatal immune system and should be encouraged, given
that novel tools are now available potentially applicable to
very small volume samples.
In parallel to the significant impact of maternal co-
infections and maternal-fetal disease transmission on neonatal
immune responses, other co-morbidities in the newborn may
have equally profound effects. One example is congenital
non-infective immunodeficiency such as severe combined im-
munodeficiency disease (SCID). BCG vaccine has a very high
rate of complications in SCID patients, as in HIV disease, with
increased vaccine-associated morbidity and mortality rates
[126]. Disseminated BCG infection in children is also linked
to rare immunodeficiencies of the IFNγ and IL12 pathways
[50]. Furthermore, acquired infections may be important. Few
studies have elucidated these interactions in the neonatal con-
text although more work has been done in older children.
Infant malaria is associated with lower IFNγ, IL5 and IL13
(i.e. Th1) responses to both BCG and tetanus immunisation
[107]. In vitro incubation of monocytes with P. falciparum-
infected red blood cells has been reported to lead to enhanced
responsiveness to TLR ligands, which may shape neonatal
immune responses [127].
Environmental
It is well established that neonatal immunity and therefore
vaccine responses vary considerably across different
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geographical settings [33]. For example, Lalor et al. demon-
strated that 3 months post-BCG immunisation, 100% of UK
infants made an IFNγ response toM.tb purified protein deriv-
ative (PPD), compared to 53% of Malawian infants in whom
responses varied by season of birth and possibly influenced by
early exposure to environmental mycobacteria, as earlier
discussed. Furthermore, there was a higher Th2- and lower
Th1-type response to PPD inMalawian infants compared with
UK infants [128]. Similarly, Hur et al. reported that both geo-
graphical location (Malawi, Gambia and UK) and season of
birth (dry vs. wet) significantly affected the cytokine profile
and immunogenicity observed in response to PPD in infants at
3 months post BCG vaccination [129]. However, the type of
assay used meant that it was not possible to show which cells
were primarily involved inmediating these differences and the
underlying mechanisms remain unclear [33].
Finally, environmental factors combined with host genetics
influence bacterial colonisation after birth and the establish-
ment of gut microbiota, regarded as crucial for optimal host
immune development. This is illustrated by the finding that
germ-free mice are at increased risk for infectious as well as
autoimmune disease [2, 130, 131] Currently, the impact of the
microbiome on early vaccine responses is still poorly under-
stood. In one study, TLR5-mediated sensing of the microbiota
was found to drive lymph node plasma cell differentiation and
enhance antibody responses to inactivated polio and influenza
vaccines [132]. Moreover, it is already well known that im-
mune responses to oral vaccines in developing countries are
suboptimal, possibly related to gut dysbiosis. Huda et al. in-
vestigated if stool microbiota composition predicted infant
oral (OPV) and parenteral (BCG, HBV, tetanus toxoid) vac-
cine responses at 6, 11 and 15weeks of age in a small group of
48 Bangladeshi infants. They demonstrated that
bifidobacterium predominance may enhance thymic develop-
ment and responses to both oral and parenteral vaccines early
in infancy. By contrast, greater bacterial diversity may cause
systemic inflammation (neutrophilia) and lower vaccine re-
sponses [133]. There is now need for similar studies in the
neonatal period.
The future: novel approaches to neonatal
immunisation
Optimise research models
In order to develop improved neonatal vaccines, better andmore
applicable research models will be required; this would enable
the accurate assessment of both vaccine immunogenicity and
safety [3, 5, 6]. Neonatal trials, even pilot studies, are fraught
with practical and ethical challenges. Nonetheless, it is not suf-
ficient to predict the response of human newborns to vaccines
from studies of older infants or adults. Equally, although animal
models, particularly neonatal ones, can provide useful insight
into early life immunity, they carry inherent disadvantages
which may preclude the direct translation of results and conclu-
sions to humans [6]. Some mammalian species, including hors-
es, pigs and ruminants, differ in the type of placentation and
relative placental and colostral transfer of immunoglobulins to
the fetus and newborn [134]. Similarly, the innate immune sys-
tem highly varies between species (e.g. murine vs. human). The
neonatal period in mice typically refers to the first 7 days of life
and therefore any experiments that exceed this time period may
not be applicable to human newborns [5, 6, 134].
Novel approaches to neonatal immunisation are threefold:
new types of vaccine configurations (varying both mechanism
of action and antigen-adjuvant formulations), new types of
vaccine delivery and new types of infant immunisation strat-
egies. These approaches aim to overcome deficiencies in neo-
natal innate and adaptive immune responses and thereby en-
able effective newborn vaccination [5]. The dynamic ability of
the early immune system to balance often opposing demands,
genetically encoded to maintain immune homeostasis versus
environmentally driven to challenge a range of potentially
pathogenic organisms, demonstrates its powerful potential
for plasticity [2].
Novel vaccine configurations
The success of neonatal BCG and HBV emphasises that (1)
sufficiently robust adaptive immune responses and functional,
seroprotective antibody titres can be generated in the newborn
period (2) this is will only occur in response to sufficiently
potent antigen-adjuvant combinations and/or appropriate cel-
lular interactions (3) ideally focus should be on potentiating
innate immune signalling pathways, particularly recruiting
and activating APCs, to help overcome adaptive immune de-
ficiencies, including Th2-type skewing and dampened Th1-
type immunity while boosting B cell responses [32, 135].
Finding a novel vaccine type is, therefore, primarily a search
for optimal antigen-adjuvant combinations that will be both
effective and safe at birth. Costly antigens and multiple vac-
cine doses may also be avoided [5].
Adjuvants boost infant immunity through multiple mecha-
nisms, including the following: activating innate immune re-
sponses; increasing half-life of the vaccine antigen by creating
a ‘depot effect’; assembling and directing antigens towards
APCs, subsequently activating them; eliciting stronger mucosal
responses; supporting cell-mediated immunity by enhancing cy-
totoxic or Th-1 type T cell function [136]. Currently alum is the
only licenced adjuvant in neonates, despite studies suggesting
that it does not promote robust Th1-type immunity [137] .
MF59, an oil-in-water emulsion recently being investigated
for use in early life adjuvanticity, assembles antigen-
containing microspheres and has been showed to have a good
safety profile. In neonatal murine models, it both induces a
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‘depot effect’, prolonging stimulation of the vaccine antigen,
and enhances APC recruitment and activity, subsequently pro-
moting CD4+ effector T cell activity and strong B and T cell
memory responses [5]. Moreover, TFH cell function is
boosted which mediates B cell adjuvanticity, with secretion
of persistently high and broader range of antibody levels [29].
Another approach to promoting robust T cell responses, in-
cluding shifting the polarisation to Th1-type immunity, is to
tackle neonatal APC impairment by exogenously administering
co-stimulatory signals. This is particularly important if endoge-
nous cytokine secretion is deficient or transcription within den-
dritic cells (DCs) is repressed, such as with IL12 [138]. As
discussed earlier, IL12 is critical in mediating DC-directed Tcell
differentiation to TFH as well as enhancing activity of cytotoxic
and Th1-type T cells. Co-administration of IL12 and influenza
subunit vaccine to newborn mice led to increased splenic ex-
pression of IFNγ, IL10 and IL15 mRNA and enhanced protec-
tive efficacy of antiviral immunisation [139]. By contrast, syn-
ergistic stimulation of DCs with at least two TLR agonists dem-
onstrates enhanced endogenous Il-12p70 production in cord
blood [140]. Given its function, effective induction of IL12 is
therefore a priority in vaccine design.
Most importantly, new vaccine formulations are being in-
vestigated that boost innate immunity by judicious targeting of
PRRs, primarily TLRs [79, 135]. Much interest has focused
on specifically stimulating TLR3, TLR7, TLR8 and TLR9
receptors, which are located within endosomes and display
robust responses to stimulation in neonates [5]. This is prob-
ably because they can utilise adenosine-refractory intracellular
pathways [141]. CpG DNA, a TLR9 ligand, has been shown
to increase pertussis toxoid-specific antibody secretion, along
with immune defence peptides and polphasphazenes, follow-
ing newborn and adult vaccination in mice [142]. Similarly,
TLR8 agonists, such as certain synthetic imidazoguinolines
and single-stranded viral RNA, are particularly effective at
stimulating human neonatal APCs in vitro as well as eliciting
TNF and IL12p40/70 secretion and promoting up-regulation
of the co-stimulatory molecule CD40 [143]. Equally, these
agonists may also mitigate the suppressive effects of T regu-
latory cells that induce APC tolerance and limit robust adap-
tive immune responses [144]. Moreover, TLR agonists medi-
ate B cell adjuvanticity, with the production of high affinity B
cell effectors, by acting on multiple innate cells including
dendritic cells and enhancing TFH responses [2]. Most recent-
ly, Dowling et al. demonstrated that TLR8 agonist nanoparti-
cles (polymersomes) mimic immunomodulatory mechanisms
seen following BCG administration, for example newborn DC
maturation profiles are similar to those induced by BCG but
with greater IL12p70 secretion [145]. In particular, the ability
to stimulate multiple TLRs simultaneously has a synergistic
effect, with recent focus on combined TLR7/TLR8 stimula-
tion to circumvent impairment of newborn APC responses.
R848 (also known as imiquimod, a type of imidazogluinoline)
ligates both TLR7 and TLR8 receptors simultaneously,
resulting in more marked production of TNFα and IL-1β than
if these sites are stimulated individually [141].
As we have seen, adjuvants in the neonatal context would
primarily help to overcome functional peculiarities of neonatal
APCs, thereby promoting both cell and humoral immunity.
Further work is required to yield more effective, targeted in-
terventions at PRR and particularly TLR 3/7/8/9 sites, while
still monitoring for reactogenicity and potentially severe ad-
verse effects, including development of toxicity, neurological
reactions or autoimmune disease [5, 6, 136].
Finally, establishing a novel mechanism of action may be
another potentially effective strategy. In particular, DNA-based
immunisation has shown promise in the context of protecting
newborn mice against malaria. Vaccinated neonates, including
those born to immune mothers, were noted to mount CD8+ T
cell-mediated protection similar to adults [146].
Novel mechanisms of vaccine delivery
Administration of neonatal vaccinations by the mucosal route
may be superior to parenteral immunisation. This is particu-
larly true for RSVand rotavirus which are responsible for the
high burden of infant respiratory and gastrointestinal diseases,
respectively, worldwide. A study by Noh et al. using a murine
model demonstrated that intranasal administration of RSV
glycoprotein core fragment (Gcf) at birth can elicit systemic
humoral immune responses and elevated IFNγ secretion,
protecting newborn mice against RSV challenge without de-
velopment of lung eosinophilia, even in the presence of high
RSV-specific maternal antibody titres [146].
Intracytoplasmic delivery of antigens is another novel option
being considered. Indeed robust neonatal adaptive responses are
dependent on the entrance of vaccine antigens in to the cyto-
plasm of APCs. To overcome potential blunting from maternal
antibodies, Chen et al. used a neonatal murine model in the
context of influenza immunisation, to show that mothers and
their offspring should be vaccinated with different vaccine types
targeting distinct antigens. The application of an attenuated
strain of the intracellular bacterium Listeria monocytogenes to
deliver heterologous antigen directly and efficiently to APC cy-
toplasm may also be a promising vaccine vehicle for the new-
born. A strong CD8+ and CD4+ Th1 type memory response
was induced, even in the presence of pre-existing maternal im-
munity. Importantly, this approach seemed to be safe in neo-
natal mice but all remains untested in human infants, given
the potentially harmful effects of this pathogen [147].
Combination strategies
Recently, there has been an interest in using neonatal vaccines as
primers (vs. single dose), in order to potentiate immune re-
sponses to homologous or heterologous boosters in later infancy.
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Dai et al. tested the immunogenicity of a heterologous prime-
boost combination against TB in neonatal mice, with the initial
DNA vaccine component given intradermally soon after birth
followed by a recombinant adenovirus vector vaccine encoding
the same antigen and given via the intranasal route at 6 weeks of
age. Results suggested that neonatal immunisation with gene-
based vaccines may create a favourable immunological environ-
ment that potentiates the pulmonary mucosal boosting, enhanc-
ing pulmonary T cell responses and therefore protection against
pulmonary TB challenge [148, 149].
Combining the administration of BCGwith other vaccines is
already an established strategy which can enhance responses to
co-delivered vaccines, as alluded to in the discussion on non-
specific effects previously. Measurements of potential vaccine
interference always form part of vaccine trials prior to the intro-
duction of a new vaccine into WHO immunisation schedules;
this principle needs to be preserved for any co-administered
vaccines in the neonatal period with the appropriate longer term
follow-up to discover any potential knock-on effects.
Figure 1 summarises remaining gaps in knowledge and
outlines research requirements for the development of the next
generation of effective vaccines aimed at newborns.
Conclusions
Effective neonatal vaccination remains a global health priority
as it may have both immunological and practical advantages
over other protective strategies in the newborn period. Three
vaccines are currently administered successfully worldwide
within the first 4 weeks of life: BCG, hepatitis B vaccine
and oral polio vaccine. The difference in their mechanism of
action, immune responses elicited and route of delivery effec-
tively demonstrates the potential for impact of this type of
immunisation on reducing morbidity and mortality of a range
of possible neonatal and infant diseases. Newborn vaccines
are also a useful and safe probe into neonatal immunity: by
enabling the controlled delivery of a well-defined immune
challenge to the naïve newborn immune system, we can de-
velop a more comprehensive understanding of protective
mechanisms in early life.
Potential barriers to successful neonatal vaccination are
multi-factorial and include the following: inherent peculiari-
ties of newborn innate and adaptive immunity limiting vac-
cine immunogenicity, intrinsic immunoregulatory mecha-
nisms, host genetic factors, prematurity, infant co-morbidities,
interference from maternal antibody, chronic maternal condi-
tions and environmental influences.
Future research must integrate lessons from early immune
ontogeny and focus on developing vaccine types with novel
mechanisms of action that engage with the unique neonatal
immune profile (Fig. 1). Optimising antigen-adjuvant combi-
nations in order to activate APCs and potentiate innate immu-
nity is key. This would promote secretion of IL-12, type I
interferons and Th1-type polarising cytokines subsequently
inducing robust Th1-type and TFH cell responses, thereby
circumventing inherent deficiencies of the newborn adaptive
Fig. 1 Summary of topics requiring further research to support of the development of future effective vaccines for use in newborns
Semin Immunopathol (2017) 39:627–642 637
immune system. Of note, a dual strategy involving newborn
immune priming with subsequent homologous or heterolo-
gous boosting may be a particularly effective tool to tackle
infections in early life. Rigorous and stringent safety analysis,
however, must underpin all of these endeavours, including an
accurate reporting system of both specific and non-specific
generalised effects of novel vaccines.
Key points
• Effective neonatal vaccination remains a global health priority with the
potential to significantly reduce infant morbidity and mortality.
• It is also a useful probing tool to improve our understanding of the
protective innate and adaptive immune mechanisms in early life.
• Only three vaccines are currently administered in the newborn period,
BCG, hepatitis B vaccine and oral polio vaccine.
• Recent advances in our understanding of immune ontogeny have
resulted in a renewed interest in neonatal immunisation.
• Other infant, maternal and environmental factors may have limiting
effects on vaccine-induced immune responses.
• Future strategies must overcome inherent deficiencies in neonatal
immunity and address any concerns regarding vaccine
immunogenicity, safety and immune interference.
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